DUBLIN – Alexion Pharmaceuticals Inc. is loading up on 'Scandi' technologies to broaden its clinical and research pipeline, striking deals with Solna, Sweden-based Affibody AB on clinical-stage "affibody" drug ABY-039, which targets the neonatal Fc receptor (FcRn), and with Copenhagen, Denmark-based Zealand Pharma A/S on an alliance to develop up to four peptide-based therapies for complement-mediated diseases.